SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-20-011679
Filing Date
2020-05-11
Accepted
2020-05-11 16:49:27
Documents
5
Effectiveness Date
2020-05-11

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS ea121643-defa14a_elitepharma.htm DEFA14A 17969
2 GRAPHIC image_001.jpg GRAPHIC 11224
3 GRAPHIC image_002.jpg GRAPHIC 8306
4 GRAPHIC image_003.jpg GRAPHIC 482863
5 GRAPHIC image_004.jpg GRAPHIC 239305
  Complete submission text file 0001213900-20-011679.txt   1005994
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

IRS No.: 223542636 | State of Incorp.: NV | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-15697 | Film No.: 20865674
SIC: 2834 Pharmaceutical Preparations